The AACR appreciates that the COVID-19 pandemic might well be impacting your health, the work ongoing in your labs, and may be placing you on the front lines to fight and care for those affected. In support of your research, particularly as it relates to COVID-19, the AACR has undertaken a number of initiatives, including the creation of a COVID-19 Task Force, the hosting of special sessions on COVID-19 and cancer at the recent AACR Virtual Annual Meetings, a special virtual conference that focused on COVID-19 and cancer, and this COVID-19 & Cancer Resource Center. This online resource brings together content related to COVID-19 from across the AACR journals as soon as it is published—and it is free to access for the duration of the pandemic.
AACR Letter to Congress
Research Articles
COVID-19 disruptions to endoscopic surveillance in Lynch syndrome
Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited
Cancer and COVID-19: On the Quest for Effective Vaccines
Viral Immunity and Vaccines in Hematologic Malignancies: Implications for COVID-19
Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System
Perspectives & Commentaries
Is COVID-19–Induced Platelet Activation a Cause of Concern for Patients with Cancer?
How did we get a COVID-19 vaccine in less than one year?
At the Crossroads: COVID-19 and Immune Checkpoint Blockade for Cancer
Is COVID-19 - induced platelet activation a cause of concern for cancer patients?
Similarities in Risk for COVID-19 and Cancer Disparities
Don't Compromise Myeloma Care Due to COVID-19 Pandemic!
COVID-19, Cancer Care and Prevention
Disparities in Cancer Prevention in the COVID-19 Era
The Paradoxical Effects of COVID-19 on Cancer Care: Current Context and Potential Lasting Impacts
Cancer Research: The Lessons to Learn from COVID-19
COVID-19 Testing in Patients with Cancer: Does One Size Fit All?
Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era
The World of Clinical Trial Development Post-Covid-19: Lessons Learned from a Global Pandemic.
The Era of COVID-19 and the Rise of Science Collectivism in Cancer Research
The COronavirus Pandemic Epidemiology (COPE) Consortium: A Call to Action
Adapting to a Pandemic — Conducting Oncology Trials during the SARS-CoV-2 Pandemic
Webinars
News
COVID-19 Prolonged in Patients with Cancer
Cancer Immunotherapies Helped Shape COVID Vaccines
Survival Factors ID'd for Patients with Blood Cancer + COVID-19
Repurposing Cancer Drugs for COVID-19
Q&A: Solange Peters on COVID-19, Cancer Intersection; Immunotherapy Biomarkers
ICI Impact on COVID-19 Severity Modest at Best
COVID-19 Challenges Status Quo for Cancer Care
COVID-19 Delays Cancer Screenings
Registries Offer Insights on COVID-19–Cancer Connection
COVID-19 Hits Cancer Research Funding
Cytokine Storm Drugs Move from CAR T to COVID-19
Clinical Research Slows as COVID-19 Surges
IL6 Blockade Reverses Anemia in AML Mice
COVID-19 More Frequent, Severe in Cancer Patients
Cancer Care Goes Virtual in Response to COVID-19
Cancer Labs Pivot to Battle COVID-19
COVID-19 Challenges Basic Researchers
Reviews
Relevance of the Bruton Tyrosine Kinase (BTK) as a target for COVID-19 therapy
TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?
Publications Division
American Association for Cancer Research
615 Chestnut Street | 17th Floor | Philadelphia, PA 19106-4404
Phone: (215) 440-9300 | Fax: (215) 440-9354 | E-mail: pubs@aacr.org